Research Funded by Box Rallies

Featured Research

Professor Selth and his team are focused on testing an entirely new strategy to treat prostate cancer with the goal of making prostate cancer more responsive to immunotherapy.

Explore Research

Improving the health and well-being of women cancer survivors

VIC

Investigating a gene that helps neuroblastomas grow blood vessels and spread throughout the body

NSW

Investigating why a new brain cancer drug works in some patients but not others

NSW

Leveraging stem-like memory T cells for effective anti-cancer mRNA vaccines

VIC

Linking gut bacteria to the development of early onset colorectal cancer using multi-omic profiling

VIC

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target

VIC

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors

NSW

Precision targeting of regulatory T cells for solid cancer immunotherapy

VIC

Predicting clinical response to breast cancer therapy – the immune signature approach

NSW

Preventing people with immune deficiencies from developing cancer

NSW

Preventing the outgrowth of cancers that spread to bone

NSW

Priming with Belinostat to chemo-sensitise high-risk neuroblastoma

NSW

Protein Biosignatures for Predicting Recurrence of Stage II Colorectal Cancer

NSW

Research Funded by Box Rallies

Featured Research

Improving the health and well-being of women cancer survivors

Investigating a gene that helps neuroblastomas grow blood vessels and spread throughout the body

Investigating why a new brain cancer drug works in some patients but not others

Leveraging stem-like memory T cells for effective anti-cancer mRNA vaccines

Linking gut bacteria to the development of early onset colorectal cancer using multi-omic profiling

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target

Melanoma Genome Mapping

Melanoma Margins Trial: A Phase III, Multi-centre Randomised Controlled Trial

Monitoring a patient’s real-time response to a new immunotherapy

Nanobody-mediated modulation of unconventional T cells for cancer immunotherapy

Novel Treatment Targets in Low-Grade Serous Ovarian Cancer

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors

Precision targeting of regulatory T cells for solid cancer immunotherapy

Predicting clinical response to breast cancer therapy – the immune signature approach

Preventing people with immune deficiencies from developing cancer

Preventing the outgrowth of cancers that spread to bone

Priming with Belinostat to chemo-sensitise high-risk neuroblastoma

Protein Biosignatures for Predicting Recurrence of Stage II Colorectal Cancer